Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients

Front Immunol. 2021 Nov 29:12:795052. doi: 10.3389/fimmu.2021.795052. eCollection 2021.

Abstract

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The immune system plays a key role in sepsis onset and remains dysregulated over time in a heterogeneous manner. Here, we decipher the heterogeneity of the first week evolution of the monocyte HLA-DR (mHLA-DR) surface protein expression in septic patients, a key molecule for adaptive immunity onset. We found and verified four distinctive trajectories endotypes in a discovery (n = 276) and a verification cohort (n = 102). We highlight that 59% of septic patients exhibit low or decreasing mHLA-DR expression while in others mHLA-DR expression increased. This study depicts the first week behavior of mHLA-DR over time after sepsis onset and shows that initial and third day mHLA-DR expression measurements is sufficient for an early risk stratification of sepsis patients. These patients might benefit from immunomodulatory treatment to improve outcomes. Going further, our study introduces a way of deciphering heterogeneity of immune system after sepsis onset which is a first step to reach a more comprehensive landscape of sepsis.

Trial registration: ClinicalTrials.gov NCT02803346 NCT02638779.

Keywords: ICU– Intensive Care Unit; endotype; flow cytometry; immune monitoring; immunosuppression; monocyte HLA-DR; sepsis; trajectory.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers
  • Cell Differentiation
  • Cell Lineage
  • Cohort Studies
  • Disease Progression
  • Female
  • HLA-DR Antigens / metabolism*
  • Humans
  • Immunomodulation
  • Male
  • Monitoring, Immunologic
  • Monocytes / immunology*
  • Phenotype
  • Prognosis
  • Sepsis / diagnosis
  • Sepsis / immunology*
  • Up-Regulation

Substances

  • Biomarkers
  • HLA-DR Antigens

Associated data

  • ClinicalTrials.gov/NCT02803346
  • ClinicalTrials.gov/NCT02638779